1-3 of 3
Martin Hutchings
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

Clinical Trials & Observations
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2024) 8 (2): 407–415.
https://doi.org/10.1182/bloodadvances.2023011920
Published: 2024
Includes: Supplemental data
Journal Articles

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma

Anna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, Mats Jerkeman, Anna Porwit, Daniel Molin, Gunilla Enblad, Arne Kolstad, Riikka Räty, Martin Hutchings, Caroline E. Weibull, Peter Hollander, Sara Ek, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5304–5313.
https://doi.org/10.1182/bloodadvances.2023010052
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4762–4770.
https://doi.org/10.1182/bloodadvances.2021004619
Published: 2021
Includes: Supplemental data